Prudential Financial Inc. Grows Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Prudential Financial Inc. increased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 26.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 231,053 shares of the company's stock after purchasing an additional 48,193 shares during the period. Prudential Financial Inc. owned 0.50% of Omnicell worth $10,286,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of OMCL. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock worth $64,573,000 after buying an additional 699,925 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Omnicell by 32.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock valued at $67,951,000 after purchasing an additional 377,883 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its holdings in shares of Omnicell by 27.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company's stock valued at $49,742,000 after purchasing an additional 243,353 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Omnicell by 46.1% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,687 shares of the company's stock worth $19,130,000 after purchasing an additional 135,650 shares during the last quarter. Finally, Pier Capital LLC acquired a new stake in shares of Omnicell during the third quarter worth $5,859,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Omnicell Price Performance

Shares of OMCL stock traded down $0.31 during midday trading on Wednesday, reaching $34.96. 59,646 shares of the company traded hands, compared to its average volume of 489,473. The firm has a market cap of $1.63 billion, a PE ratio of 129.15, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The firm's 50 day simple moving average is $38.71 and its two-hundred day simple moving average is $42.46. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, equities research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

OMCL has been the topic of several recent research reports. Benchmark reissued a "buy" rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America cut their price target on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. JPMorgan Chase & Co. lowered their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, March 20th. Wells Fargo & Company cut their target price on Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, StockNews.com cut Omnicell from a "buy" rating to a "hold" rating in a report on Monday, March 24th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $51.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.